Jonah Dallas Yakel alias The Brain Reversal Chiro

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to advertise Cognitive decline, dementia, and Alzheimer's disease as within their scope of practice.

Cognitive decline, dementia, and Alzheimer's disease

Supports

High-quality evidence shows that dementia, Alzheimer’s disease, and broader cognitive decline are common clinical entities with identifiable risk factors and modifiable influences, which supports the general claim that these conditions are real, prevalent, and affected by multiple domains of health. A Cochrane-systematic-review-level paper on multidomain interventions for dementia prevention reports that combined lifestyle and risk-factor management (diet, physical activity, cognitive training, vascular risk control) can produce small but statistically significant improvements in cognitive function in older adults at risk, though effects on incident dementia are limited, supporting the idea that cognitive decline and dementia are modifiable to a degree. ^[4] A systematic review and meta-analysis on diabetes medications finds that certain antidiabetic drugs (especially GLP‑1 receptor agonists and thiazolidinediones) are associated with reduced future dementia risk, indicating that metabolic health and pharmacologic management can influence dementia and cognitive decline outcomes. ^[1][3] Another systematic review of multidomain lifestyle interventions concludes that two‑thirds of included trials show improvement in cognition in older adults at risk of dementia when interventions target diet, physical activity, and cognitive training, suggesting that cognitive decline can be slowed or partially prevented in at‑risk populations. Systematic reviews of renal dysfunction and cognitive outcomes suggest that albuminuria and other kidney indicators are associated with an increased risk of cognitive impairment and dementia, supporting the concept of a brain–kidney axis where systemic disease contributes to neurodegeneration. ^[2]

Contradicts

The indexed evidence does not contradict the existence or clinical importance of cognitive decline, dementia, or Alzheimer’s disease; rather, it shows that while these are major public health problems, the effectiveness of preventive or therapeutic strategies is often modest and inconsistent. ^{[5][6][7][8][9][10][11][12]} The Cochrane-level multidomain intervention review reports no clear reduction in incident dementia despite small improvements in cognitive scores, indicating that current lifestyle-based prevention strategies have limited proven capacity to prevent dementia itself, and evidence is heterogeneous and sometimes at risk of bias. ^[1][4] Systematic reviews of antidiabetic drugs show protective associations for some agents but inconsistent or neutral findings for others, and many data come from observational studies with potential confounding, meaning that drug effects on dementia risk are not uniformly strong and causality is not fully established. ^[3] Brain–kidney axis evidence from renal dysfunction meta-analyses shows associations with dementia risk, but authors emphasize that the evidence base still needs strengthening, suggesting that mechanistic and interventional data are not yet robust enough to support strong claims about reversing or definitively preventing cognitive decline through kidney-focused interventions alone. ^[2]

Mainstream view

The mainstream medical and scientific position is that cognitive decline, dementia, and Alzheimer’s disease are common, clinically well‑defined conditions caused by complex interactions of neurodegenerative pathology, vascular factors, metabolic and systemic disease, and life‑course exposures, and that they represent major global health burdens. ^[4] Current consensus is that no single intervention can reliably prevent Alzheimer’s disease or dementia, but multidomain strategies—addressing cardiovascular and metabolic risk, physical activity, diet, cognitive and social engagement, hearing/vision management, and appropriate medications—can modestly improve cognitive trajectories and may delay onset in some high‑risk individuals. ^[2][3] Pharmacologic approaches (including selected diabetes medications) and risk-factor modification are regarded as promising adjuncts, yet guidelines generally frame these as risk-reduction strategies with partial, not curative, effects, and emphasize that evidence remains mixed and evolving. ^[1]

In their own wordsView sourceArchived copy

“Cognitive decline, dementia, and Alzheimer's disease”

Rule: K.S.A. 65-2912(a)(6)-(7) (analogous scope/discipline limits for non‑physician providers)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure Anxiety and depression.

Anxiety and depression

Supports

The influencer’s claim is extremely vague (“Anxiety and depression”) and does not specify any particular mechanism or treatment, but there is extensive high‑quality evidence that anxiety disorders and depressive disorders are common, clinically significant conditions with effective treatments. ^[13] Systematic reviews and major guidelines consistently support that structured psychological interventions, especially cognitive behavioral therapy (CBT), are effective for both anxiety and depression across diverse populations, including primary care patients, those with chronic medical illness, and university students, with small to large effect sizes on symptom reduction. ^[20] Large practice guidelines from WHO, national psychiatric associations, and evidence-informed clinical practice guidelines recommend CBT and related structured psychotherapies as first-line treatments for generalized anxiety disorder, panic disorder, and mild to moderate major depressive disorder, and as key components of care for more severe depression, often in combination with antidepressant medication. ^{[14][15][16][17][18][19]} Systematic metareviews and guideline summaries show that selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have robust evidence from randomized controlled trials and meta-analyses for reducing symptoms in generalized anxiety disorder and major depressive disorder, particularly when functional impairment is marked, and that combining pharmacotherapy with psychotherapy improves outcomes compared with either alone. Multiple systematic reviews and meta-analyses demonstrate benefit from additional or adjunctive interventions (e. g. , breathing exercises, physical exercise, collaborative care models, neurofeedback, saffron supplementation) for anxiety and depression in specific populations, although these are generally regarded as adjuncts rather than primary treatments. Overall, mainstream high‑quality evidence strongly supports that anxiety and depression are treatable medical conditions and that structured psychotherapy and, where appropriate, antidepressant pharmacotherapy provide clinically meaningful improvement.

Contradicts

Because the influencer’s claim is not specific, there is no single discrete statement to be contradicted, but high‑quality evidence does contradict several common misinformation themes around anxiety and depression. ^[14][17] Major guidelines and systematic reviews do not support the idea that anxiety and depression are trivial, purely “mind over matter,” or best managed only with lifestyle changes in moderate to severe cases; instead they indicate that untreated moderate to severe anxiety and depression carry significant morbidity, impaired functioning, and long‑term health risks, and that evidence‑based psychotherapies and, when indicated, pharmacotherapies are necessary for optimal outcomes. ^[16][20] High‑quality sources also do not support the notion that a single supplement, breathing technique, or alternative therapy can reliably cure anxiety or depression in the general population; while meta-analyses show benefits of interventions like breathing exercises, gratitude practices, and saffron, these effects are modest, population‑specific, and insufficient to replace standard care. Guidelines explicitly caution against routine long‑term benzodiazepine use for anxiety and against antidepressant use in children with anxiety disorders, which contradicts any unqualified “medication for everyone” message; they also emphasize that antidepressants alone should not be the default first‑line treatment for most adults with moderate depression when psychological interventions are available. ^{[13][15][18][19]} Where evidence is weaker, systematic reviews highlight heterogeneity and methodological limitations in newer or more experimental approaches (such as some neurofeedback protocols or novel supplements), underscoring that these should be considered adjunctive or investigational rather than proven core treatments. In sum, if the influencer implies that anxiety and depression are either not real medical conditions or are reliably curable by a single non‑evidence‑based approach, that is not supported by current high-quality evidence.

Mainstream view

The mainstream medical and scientific position is that anxiety disorders and depressive disorders are common, serious, and heterogeneous mental health conditions with multifactorial causes, including biological, psychological, and social factors. ^[13][14][20] They are diagnosed using standardized criteria (such as DSM or ICD), often co-occur, and are associated with significant distress, functional impairment, and elevated risk of suicide and other adverse health outcomes. For generalized anxiety disorder, panic disorder, and major depressive disorder, major guidelines recommend structured psychological interventions—especially cognitive behavioral therapy, interpersonal therapy, and related modalities—as first-line treatments, particularly for mild to moderate presentations, and as essential components of care for more severe illness. ^{[15][16][17][18]} Pharmacotherapy with antidepressants, mainly SSRIs and SNRIs, is strongly evidence‑based and widely recommended for moderate to severe depression and functionally impairing anxiety, typically in combination with psychotherapy where feasible; continuation for at least several months after remission reduces relapse risk. Benzodiazepines are not considered first-line for chronic anxiety and are reserved for short-term management of acute severe anxiety, with careful tapering. For children and adolescents, drug treatment for anxiety and depression is more restricted, and guidelines emphasize psychological therapies as the primary modality. ^[19] Adjunctive interventions such as physical exercise, stress management, mindfulness-based therapies, breathing exercises, and collaborative care models are recognized as helpful additions, but they are Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).

In their own wordsView sourceArchived copy

“Anxiety and depression”

Rule: K.S.A. 65-2912(a)(6)-(7)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure Autoimmune conditions.

Autoimmune conditions

Supports

The only indexed paper directly relevant to the influencer’s very general claim about autoimmune conditions is the systematic review and meta-analysis on autoimmune disorders in oral lichen planus. ^[21] Those reviewer reports relate to a published meta-analysis showing comorbidity between oral lichen planus (OLP) and autoimmune thyroid disease and diabetes mellitus. This supports the more general concept that specific autoimmune conditions tend to cluster and co-occur in the same individual, because OLP patients show increased rates of other autoimmune diseases. ^[24] High‑quality recent reviews and background chapters from academic search further support that autoimmune diseases are a broad class of disorders characterized by immune responses directed against self-antigens, involving breakdown of immune tolerance and multifactorial genetic and environmental risk factors, consistent with standard immunology and rheumatology texts and NIH overviews. Large epidemiologic reviews and consensus articles also support that the overall prevalence of autoimmune diseases is rising globally, and that autoantibodies can precede clinical disease by years, again aligning with the general medical concept of autoimmune conditions as chronic, progressive illnesses. ^[23] Guidelines and major reviews further support that autoimmune diseases often share pathophysiologic mechanisms (e. g. , Th17 skewing, regulatory T‑cell dysfunction, inflammasome activation), and that many patients are at increased risk for additional autoimmune diseases or related complications such as cardiovascular disease and certain cancers. Overall, the indexed systematic review on OLP plus mainstream reviews from academic search support the broad notion that autoimmune conditions are real, biologically grounded entities, frequently comorbid, and associated with chronic morbidity.

Contradicts

The provided index papers are largely not directly about broad influencer‑style claims on autoimmune conditions; most are specific clinical trials (e. g. , DNA sequencing in practice, perioperative analgesia, platelet‑rich fibrin, cryptosporidiosis treatment) that do not address autoimmune pathogenesis, diagnosis, or treatment, and therefore cannot be used to substantiate sweeping claims about autoimmune conditions. ^[24] The reviewer reports for the oral lichen planus meta-analysis themselves highlight that, beyond autoimmune thyroid disease and type 1 diabetes, evidence linking OLP to other autoimmune disorders (fibromyalgia, rheumatic diseases, Sjögren’s, lupus, dermatologic diseases, gastrointestinal autoimmune disorders) is weak, inconsistent, or in need of better-quality studies, indicating limits to how far comorbidity claims can be generalized. ^[21][23] Broader academic reviews emphasize that although autoimmune diseases share certain immune mechanisms, they are heterogeneous conditions and not a single entity with a unified cause or simple cure; this contradicts common influencer narratives that treat “autoimmunity” as one monolithic syndrome that can be reversed with single lifestyle or supplement interventions. ^[22] Major reviews also note that, despite progress in targeted therapies and immunomodulatory approaches, many autoimmune diseases still lack curative treatments and require long-term management, again countering simplistic cure claims. Because the influencer’s actual claim is unspecified and only labeled as “Autoimmune conditions,” there is no high‑quality evidence in the indexed papers that would support any strong, nonstandard assertion (e. g. , that most chronic symptoms are unrecognized autoimmunity or that autoimmunity can generally be cured quickly).

Mainstream view

Mainstream medical and scientific consensus views autoimmune conditions as a diverse group of diseases in which the immune system mounts pathogenic responses against self-tissues, driven by a combination of genetic susceptibility, environmental triggers, and dysregulated immune tolerance. ^[24] Autoimmune diseases are defined and classified based on reproducible clinical criteria, characteristic autoantibodies or cellular immune findings, and often supported by animal models and mechanistic data. They are common, with increasing incidence and prevalence documented in large epidemiologic studies, and they frequently co-occur; patients with one autoimmune disease have a higher-than-expected risk of developing additional autoimmune disorders, as illustrated by the comorbidity between oral lichen planus and autoimmune thyroid disease and type 1 diabetes. ^[21][22][23] At the same time, mainstream medicine recognizes substantial heterogeneity: different autoimmune diseases affect distinct organs, have varied clinical courses (from mild to life‑threatening), and respond differently to treatments. Standard of care focuses on accurate diagnosis, risk stratification, and long‑term management using immunosuppressive and immunomodulatory therapies, biologics, and, increasingly, targeted molecular agents, aiming for disease Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).

In their own wordsView sourceArchived copy

“Autoimmune conditions”

Rule: K.S.A. 65-2912(a)(6)-(7)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to advertise Mold and Lyme related illness as within their scope of practice.

Mold and Lyme related illness

Supports

The influencer claim appears to be that mold-related illness and Lyme-related illness are meaningfully linked or interact clinically. None of the user-provided index papers address mold–Lyme interactions; they focus on unrelated topics such as DNA sequencing, anesthetic regimens, mucosal healing, cryptosporidiosis treatment, employment after critical illness, and suicide methods. From broader academic and guideline literature (outside the index list), there is support for the idea that Lyme disease can coexist with other infections (tick‑borne coinfections like Babesia, Anaplasma, Ehrlichia, Bartonella), which can complicate clinical course and contribute to treatment failure. ^[25][26] There is also evidence that environmental mold exposure and mycotoxins can cause respiratory and allergic disease and, in some settings, systemic illness, and that both mycotoxins and chronic infections can affect the immune system and inflammatory pathways. This provides a biologically plausible basis for interactions in severely ill or immunocompromised patients, including those with Lyme disease, even though direct RCT-level evidence is lacking.

Contradicts

The index literature provided does not support any specific, strong causal claim that mold exposure is a common cause of Lyme disease, or that treating mold is a validated core component of evidence‑based Lyme management. High‑quality systematic reviews and guideline documents on Lyme disease emphasize tick‑borne bacteria and recognized coinfections, but they do not identify mold illness or mycotoxin exposure as established coinfections or standard treatment targets. A systematic review on chronic tick‑borne coinfections concluded that the medical literature does not support the diagnosis of chronic, atypical tick‑borne coinfections in patients with chronic nonspecific illnesses, highlighting that many proposed chronic co‑infection diagnoses lack robust evidence. By analogy, many of the strong claims in influencer and functional‑medicine circles that mold and Lyme "work together" to keep patients sick, that mold is a leading cause of persistent Lyme symptoms, or that specialized "mold detox" protocols are necessary, go beyond what controlled trials, major guidelines, or rigorous systematic reviews currently support. ^[26] Evidence specifically linking mold exposure to increased Lyme infection risk, failure of standard Lyme therapy, or a distinct combined syndrome with validated diagnostic criteria is weak and largely based on case series, expert opinion, and mechanistic speculation rather than high‑quality RCTs or meta‑analyses. ^[25]

Mainstream view

Mainstream infectious‑disease and environmental‑health positions are that Lyme disease is a tick‑borne bacterial infection caused primarily by Borrelia burgdorferi (and related species), sometimes accompanied by other tick‑borne coinfections (e. g. , Babesia, Anaplasma, Ehrlichia, Bartonella), and that diagnosis and treatment should follow established evidence‑based criteria. Mold and damp indoor environments are recognized causes of respiratory and allergic disease and can produce mycotoxins, which in some circumstances contribute to systemic illness, particularly in immunocompromised hosts, but mold illness is not currently considered a standard coinfection of Lyme disease nor a validated primary driver of typical post‑treatment Lyme symptoms in major guidelines. ^[25] The mainstream view is that it is possible for an individual to have both mold‑related illness and Lyme disease, and that overlapping nonspecific symptoms (fatigue, cognitive complaints, pain) can occur, but rigorous evidence showing that mold exposure commonly causes, sustains, or substantially modifies Lyme disease is limited. ^[26] Clinicians are encouraged to evaluate each condition with its own evidence‑based diagnostic framework rather than assuming a unified "mold–Lyme" syndrome in the absence of high‑quality supporting data.

In their own wordsView sourceArchived copy

“Mold and Lyme related illness”

Rule: K.S.A. 65-2912(a)(6)-(7)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure healing from CIRS.

healing from CIRS

Supports

High-quality evidence specifically on Chronic Inflammatory Response Syndrome (CIRS) is limited but not entirely absent. ^[31][32][33] A recent peer‑reviewed literature review (systematic‑style narrative review) reports 13 published articles (14 studies) on CIRS treatment, including two randomized controlled trials, and concludes that the Shoemaker Protocol is the only treatment with documented clinical efficacy, with statistically significant improvements in objective biomarkers and symptoms across multiple clinical studies. ^[27] This review supports the perspective that CIRS represents an inflammatory-based illness characterized by innate immune dysregulation following exposure to water‑damaged buildings and that it can be clinically improved with a structured treatment protocol. Additional academic and professional narratives describe CIRS as a sustained innate immune response syndrome with characteristic biomarker abnormalities (e. g. , C4a, TGF‑β1, MMP‑9, low MSH, abnormal visual contrast sensitivity) and transcriptomic signatures such as “molecular hypometabolism,” suggesting a reproducible pattern of immune and metabolic disruption in affected patients. ^[34] These sources, while not large-scale RCTs or formal guideline statements, provide some empirical support that a definable clinical entity associated with chronic inflammatory responses to biotoxins can be identified and treated within specialized practice models. ^[28]

Contradicts

Mainstream guidelines and major evidence-based bodies do not currently recognize CIRS as an established diagnosis. ^[29][27] A clinical policy review states explicitly that chronic inflammatory response syndrome is considered an investigational or not clinically proven diagnosis and therefore not medically necessary, noting that it is not recognized as a pathologic entity in major biomedical databases, lacks an ICD coding designation, and has no unifying clinical studies that establish a clear disease entity linking proposed laboratory and environmental findings. ^[32] This review emphasizes inconsistent definitions, limited large-scale studies, and reliance on single-author narrative reviews that may not have undergone robust peer review. Broader guideline documents on hypertension, parenteral nutrition, and clinical nutrition in inflammatory bowel disease focus extensively on chronic inflammation as a mechanism but do not mention CIRS or endorse it as a distinct syndrome. ^[28][30][33] Overall, the available high-quality guideline-level evidence either ignores CIRS altogether or explicitly classifies it as unproven, indicating that current evidence is considered too weak, too narrow in scope, or too methodologically limited to support widespread clinical adoption.

Mainstream view

The mainstream medical position is that chronic inflammation is a key driver of many diseases, but Chronic Inflammatory Response Syndrome, as defined in Shoemaker-style protocols, is not an established, widely accepted diagnostic entity. ^[32][33] Major specialty guidelines for cardiovascular disease, parenteral nutrition, and inflammatory bowel disease address chronic inflammatory mechanisms and management without recognizing CIRS as a formal syndrome. ^[27][28][30] Health-plan and policy reviews explicitly classify CIRS as investigational and not clinically proven, citing the absence of consensus diagnostic criteria across mainstream organizations, lack of ICD coding, and insufficient large, independent, peer‑reviewed trials linking proposed biomarkers and environmental exposures into a validated disease construct. ^[34] Within functional and integrative medicine circles, CIRS is more often regarded as a real but emerging condition with a growing research base, yet mainstream academic and regulatory bodies continue to treat it as experimental and controversial pending more rigorous, independent, and large-scale evidence. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).

In their own wordsView sourceArchived copy

“healing from CIRS”

Rule: K.S.A. 65-2912(a)(6)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure CIRS+.

CIRS+

Supports

High-quality evidence specifically on Chronic Inflammatory Response Syndrome (CIRS) is limited but not entirely absent. ^[31][32][33] A recent peer‑reviewed literature review (systematic‑style narrative review) reports 13 published articles (14 studies) on CIRS treatment, including two randomized controlled trials, and concludes that the Shoemaker Protocol is the only treatment with documented clinical efficacy, with statistically significant improvements in objective biomarkers and symptoms across multiple clinical studies. ^[27] This review supports the perspective that CIRS represents an inflammatory-based illness characterized by innate immune dysregulation following exposure to water‑damaged buildings and that it can be clinically improved with a structured treatment protocol. Additional academic and professional narratives describe CIRS as a sustained innate immune response syndrome with characteristic biomarker abnormalities (e. g. , C4a, TGF‑β1, MMP‑9, low MSH, abnormal visual contrast sensitivity) and transcriptomic signatures such as “molecular hypometabolism,” suggesting a reproducible pattern of immune and metabolic disruption in affected patients. ^[34] These sources, while not large-scale RCTs or formal guideline statements, provide some empirical support that a definable clinical entity associated with chronic inflammatory responses to biotoxins can be identified and treated within specialized practice models. ^[28]

Contradicts

Mainstream guidelines and major evidence-based bodies do not currently recognize CIRS as an established diagnosis. ^[29][27] A clinical policy review states explicitly that chronic inflammatory response syndrome is considered an investigational or not clinically proven diagnosis and therefore not medically necessary, noting that it is not recognized as a pathologic entity in major biomedical databases, lacks an ICD coding designation, and has no unifying clinical studies that establish a clear disease entity linking proposed laboratory and environmental findings. ^[32] This review emphasizes inconsistent definitions, limited large-scale studies, and reliance on single-author narrative reviews that may not have undergone robust peer review. Broader guideline documents on hypertension, parenteral nutrition, and clinical nutrition in inflammatory bowel disease focus extensively on chronic inflammation as a mechanism but do not mention CIRS or endorse it as a distinct syndrome. ^[28][30][33] Overall, the available high-quality guideline-level evidence either ignores CIRS altogether or explicitly classifies it as unproven, indicating that current evidence is considered too weak, too narrow in scope, or too methodologically limited to support widespread clinical adoption.

Mainstream view

The mainstream medical position is that chronic inflammation is a key driver of many diseases, but Chronic Inflammatory Response Syndrome, as defined in Shoemaker-style protocols, is not an established, widely accepted diagnostic entity. ^[32][33] Major specialty guidelines for cardiovascular disease, parenteral nutrition, and inflammatory bowel disease address chronic inflammatory mechanisms and management without recognizing CIRS as a formal syndrome. ^[27][28][30] Health-plan and policy reviews explicitly classify CIRS as investigational and not clinically proven, citing the absence of consensus diagnostic criteria across mainstream organizations, lack of ICD coding, and insufficient large, independent, peer‑reviewed trials linking proposed biomarkers and environmental exposures into a validated disease construct. ^[34] Within functional and integrative medicine circles, CIRS is more often regarded as a real but emerging condition with a growing research base, yet mainstream academic and regulatory bodies continue to treat it as experimental and controversial pending more rigorous, independent, and large-scale evidence. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).

In their own wordsView sourceArchived copy

“CIRS+”

Rule: K.S.A. 65-2912(a)(6)-(7)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure The CIRS Brain Solution.

The CIRS Brain Solution

Supports

High-quality evidence specifically on Chronic Inflammatory Response Syndrome (CIRS) is limited but not entirely absent. ^[31][32][33] A recent peer‑reviewed literature review (systematic‑style narrative review) reports 13 published articles (14 studies) on CIRS treatment, including two randomized controlled trials, and concludes that the Shoemaker Protocol is the only treatment with documented clinical efficacy, with statistically significant improvements in objective biomarkers and symptoms across multiple clinical studies. ^[27] This review supports the perspective that CIRS represents an inflammatory-based illness characterized by innate immune dysregulation following exposure to water‑damaged buildings and that it can be clinically improved with a structured treatment protocol. Additional academic and professional narratives describe CIRS as a sustained innate immune response syndrome with characteristic biomarker abnormalities (e. g. , C4a, TGF‑β1, MMP‑9, low MSH, abnormal visual contrast sensitivity) and transcriptomic signatures such as “molecular hypometabolism,” suggesting a reproducible pattern of immune and metabolic disruption in affected patients. ^[34] These sources, while not large-scale RCTs or formal guideline statements, provide some empirical support that a definable clinical entity associated with chronic inflammatory responses to biotoxins can be identified and treated within specialized practice models. ^[28]

Contradicts

Mainstream guidelines and major evidence-based bodies do not currently recognize CIRS as an established diagnosis. ^[29][27] A clinical policy review states explicitly that chronic inflammatory response syndrome is considered an investigational or not clinically proven diagnosis and therefore not medically necessary, noting that it is not recognized as a pathologic entity in major biomedical databases, lacks an ICD coding designation, and has no unifying clinical studies that establish a clear disease entity linking proposed laboratory and environmental findings. ^[32] This review emphasizes inconsistent definitions, limited large-scale studies, and reliance on single-author narrative reviews that may not have undergone robust peer review. Broader guideline documents on hypertension, parenteral nutrition, and clinical nutrition in inflammatory bowel disease focus extensively on chronic inflammation as a mechanism but do not mention CIRS or endorse it as a distinct syndrome. ^[28][30][33] Overall, the available high-quality guideline-level evidence either ignores CIRS altogether or explicitly classifies it as unproven, indicating that current evidence is considered too weak, too narrow in scope, or too methodologically limited to support widespread clinical adoption.

Mainstream view

The mainstream medical position is that chronic inflammation is a key driver of many diseases, but Chronic Inflammatory Response Syndrome, as defined in Shoemaker-style protocols, is not an established, widely accepted diagnostic entity. ^[32][33] Major specialty guidelines for cardiovascular disease, parenteral nutrition, and inflammatory bowel disease address chronic inflammatory mechanisms and management without recognizing CIRS as a formal syndrome. ^[27][28][30] Health-plan and policy reviews explicitly classify CIRS as investigational and not clinically proven, citing the absence of consensus diagnostic criteria across mainstream organizations, lack of ICD coding, and insufficient large, independent, peer‑reviewed trials linking proposed biomarkers and environmental exposures into a validated disease construct. ^[34] Within functional and integrative medicine circles, CIRS is more often regarded as a real but emerging condition with a growing research base, yet mainstream academic and regulatory bodies continue to treat it as experimental and controversial pending more rigorous, independent, and large-scale evidence. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).

In their own wordsView sourceArchived copy

“The CIRS Brain Solution”

Rule: K.S.A. 65-2912(a)(6)-(7)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to advertise Claims to treat neurodegenerative disease and dementia/Alzheimer's beyond chiropractic scope as within their scope of practice.

Claims to treat neurodegenerative disease and dementia/Alzheimer's beyond chiropractic scope

Supports

The influencer’s claim is too vague to directly assess, but high-quality evidence exists regarding Alzheimer’s disease diagnosis, treatment, and prevention that may partially support general statements such as “there are effective interventions” or “lifestyle changes matter. ” A large systematic review and meta-analysis of preventive strategies (243 prospective observational studies and 153 randomized trials) found that multiple modifiable risk factors (e. ^[36] g. , physical activity, cognitive engagement, vascular risk control) are associated with reduced Alzheimer’s risk, supporting the idea that Alzheimer’s disease risk is not fixed and can be influenced by lifestyle and medical management. Exercise interventions in patients with Alzheimer’s disease show small to moderate benefits on cognition, global functioning, and activities of daily living, indicating that structured physical activity is a meaningful nonpharmacologic intervention even after diagnosis. Disease-modifying monoclonal antibodies targeting amyloid (donanemab, lecanemab, aducanumab) have demonstrated statistically significant but modest slowing of cognitive decline in mild cognitive impairment due to Alzheimer’s disease and early Alzheimer’s dementia in randomized trials, as summarized in a systematic review and network meta-analysis, supporting claims that some drugs can alter disease trajectory rather than only treat symptoms. ^[5][35] The Alzheimer’s Association clinical practice guideline on blood-based biomarkers concludes that certain plasma biomarkers (e. ^[37] g. , Aβ42/40, p-tau species, neurofilament light) can support diagnosis and workup of suspected Alzheimer’s disease in specialized settings, supporting claims that blood tests are beginning to be integrated into diagnostic pathways, though primarily as adjuncts rather than standalone tests.

Contradicts

Because the claim is unspecified (“Alzheimer”), any categorical statements such as “Alzheimer’s is fully preventable,” “current drugs cure Alzheimer’s,” or “simple blood tests can definitively diagnose Alzheimer’s in anyone” would be contradicted by the high-quality evidence. The large prevention meta-analysis emphasizes that most data are observational, effect sizes are modest, and interventions lower risk but do not eliminate it; Alzheimer’s remains a multifactorial neurodegenerative disease with strong age and genetic components, so claims of complete prevention are not evidence-based. ^[35][36] The network meta-analysis of donanemab, lecanemab, aducanumab, and lithium shows only modest improvements or slowing of decline and notes safety/tolerability concerns such as amyloid-related imaging abnormalities; this contradicts any claim that these agents “reverse” or “cure” Alzheimer’s or lead to large functional recoveries. ^[5] Exercise meta-analyses in Alzheimer’s disease find benefits that are real but typically small to moderate, contradicting exaggerated claims that exercise alone can stop or dramatically reverse the disease process. The Alzheimer’s Association guideline on blood-based biomarkers explicitly positions them as tools to support diagnosis within specialized centers, not as standalone screening or definitive diagnostic tools for the general population, so claims that a single blood test can completely replace clinical evaluation, neuroimaging, and CSF testing are not supported. ^[37]

Mainstream view

Mainstream medical consensus views Alzheimer’s disease as a progressive neurodegenerative disorder characterized by cognitive decline, functional impairment, and characteristic neuropathology (amyloid and tau), with age and genetics (especially APOE) as major risk factors. ^[5] Evidence-based guidelines recognize that risk can be modified but not eliminated through control of vascular risk factors, physical activity, cognitive and social engagement, and other lifestyle interventions, based largely on observational data and some randomized trials. ^[35][36] Pharmacologic disease-modifying therapies such as donanemab, lecanemab, and aducanumab are considered to offer modest slowing of decline in carefully selected patients with early-stage disease, with significant safety, cost, and access considerations; they are not regarded as cures. Nonpharmacologic interventions, especially exercise, are recommended as part of comprehensive care, with expectations of modest benefits in cognition and function rather than disease reversal. Diagnostic practice is moving toward incorporating blood-based biomarkers as adjuncts to clinical assessment and imaging within specialized memory clinics, but these tests are not yet considered standalone diagnostic tools or general-population screening methods. ^[37] Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).

In their own wordsView sourceArchived copy

“#alzheimer”

Rule: K.S.A. 65-2912(a)(6)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to advertise Claims to diagnose/treat Lyme and mold-related systemic illness as within their scope of practice.

Claims to diagnose/treat Lyme and mold-related systemic illness

Supports

No high-quality evidence in the provided index papers supports the standalone claim “mold” as a medical assertion. The listed peer-reviewed papers are unrelated guideline articles on hypertension, nutrition, and inflammatory bowel disease, so they do not provide supportive evidence for a general claim about mold exposure or mold illness . ^[29][28][30]

Contradicts

The claim is too vague to evaluate as written, and the provided index papers do not address mold at all; therefore they neither support nor meaningfully test it . In mainstream medical literature, indoor dampness and visible mold are associated with respiratory symptoms and asthma exacerbation, but broad claims that mold causes nonspecific systemic illness in most people are not established by major guidelines or high-quality trials. ^[27] Because no mold-specific peer-reviewed index paper was supplied, there is no direct evidence here supporting a strong mold-toxicity claim.

Mainstream view

Mainstream medicine recognizes that damp indoor environments and mold can worsen allergies, asthma, and some respiratory symptoms, and remediation of moisture problems is recommended. Broad claims that mold commonly causes chronic multisystem illness are not supported by strong consensus evidence, especially without a clear exposure history, symptom pattern, and objective findings. ^{[29][27][28][30]}

In their own wordsView sourceArchived copy

“#mold”

Rule: K.S.A. 65-2912(a)(6)-(7)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to advertise Claims to heal from CIRS, a contested systemic illness model as within their scope of practice.

Claims to heal from CIRS, a contested systemic illness model

Supports

High-quality evidence specifically on Chronic Inflammatory Response Syndrome (CIRS) is limited but not entirely absent. ^[31][32][33] A recent peer‑reviewed literature review (systematic‑style narrative review) reports 13 published articles (14 studies) on CIRS treatment, including two randomized controlled trials, and concludes that the Shoemaker Protocol is the only treatment with documented clinical efficacy, with statistically significant improvements in objective biomarkers and symptoms across multiple clinical studies. ^[27] This review supports the perspective that CIRS represents an inflammatory-based illness characterized by innate immune dysregulation following exposure to water‑damaged buildings and that it can be clinically improved with a structured treatment protocol. Additional academic and professional narratives describe CIRS as a sustained innate immune response syndrome with characteristic biomarker abnormalities (e. g. , C4a, TGF‑β1, MMP‑9, low MSH, abnormal visual contrast sensitivity) and transcriptomic signatures such as “molecular hypometabolism,” suggesting a reproducible pattern of immune and metabolic disruption in affected patients. ^[34] These sources, while not large-scale RCTs or formal guideline statements, provide some empirical support that a definable clinical entity associated with chronic inflammatory responses to biotoxins can be identified and treated within specialized practice models. ^[28]

Contradicts

Mainstream guidelines and major evidence-based bodies do not currently recognize CIRS as an established diagnosis. ^[29][27] A clinical policy review states explicitly that chronic inflammatory response syndrome is considered an investigational or not clinically proven diagnosis and therefore not medically necessary, noting that it is not recognized as a pathologic entity in major biomedical databases, lacks an ICD coding designation, and has no unifying clinical studies that establish a clear disease entity linking proposed laboratory and environmental findings. ^[32] This review emphasizes inconsistent definitions, limited large-scale studies, and reliance on single-author narrative reviews that may not have undergone robust peer review. Broader guideline documents on hypertension, parenteral nutrition, and clinical nutrition in inflammatory bowel disease focus extensively on chronic inflammation as a mechanism but do not mention CIRS or endorse it as a distinct syndrome. ^[28][30][33] Overall, the available high-quality guideline-level evidence either ignores CIRS altogether or explicitly classifies it as unproven, indicating that current evidence is considered too weak, too narrow in scope, or too methodologically limited to support widespread clinical adoption.

Mainstream view

The mainstream medical position is that chronic inflammation is a key driver of many diseases, but Chronic Inflammatory Response Syndrome, as defined in Shoemaker-style protocols, is not an established, widely accepted diagnostic entity. ^[32][33] Major specialty guidelines for cardiovascular disease, parenteral nutrition, and inflammatory bowel disease address chronic inflammatory mechanisms and management without recognizing CIRS as a formal syndrome. ^[27][28][30] Health-plan and policy reviews explicitly classify CIRS as investigational and not clinically proven, citing the absence of consensus diagnostic criteria across mainstream organizations, lack of ICD coding, and insufficient large, independent, peer‑reviewed trials linking proposed biomarkers and environmental exposures into a validated disease construct. ^[34] Within functional and integrative medicine circles, CIRS is more often regarded as a real but emerging condition with a growing research base, yet mainstream academic and regulatory bodies continue to treat it as experimental and controversial pending more rigorous, independent, and large-scale evidence. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).

In their own wordsView sourceArchived copy

“#cirs”

Rule: K.S.A. 65-2912(a)(6)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to advertise CIRS and mold-related illness healing protocols as within their scope of practice.

CIRS and mold-related illness healing protocols

Supports

High-quality evidence specifically on Chronic Inflammatory Response Syndrome (CIRS) is limited but not entirely absent. ^[31][32][33] A recent peer‑reviewed literature review (systematic‑style narrative review) reports 13 published articles (14 studies) on CIRS treatment, including two randomized controlled trials, and concludes that the Shoemaker Protocol is the only treatment with documented clinical efficacy, with statistically significant improvements in objective biomarkers and symptoms across multiple clinical studies. ^[27] This review supports the perspective that CIRS represents an inflammatory-based illness characterized by innate immune dysregulation following exposure to water‑damaged buildings and that it can be clinically improved with a structured treatment protocol. Additional academic and professional narratives describe CIRS as a sustained innate immune response syndrome with characteristic biomarker abnormalities (e. g. , C4a, TGF‑β1, MMP‑9, low MSH, abnormal visual contrast sensitivity) and transcriptomic signatures such as “molecular hypometabolism,” suggesting a reproducible pattern of immune and metabolic disruption in affected patients. ^[34] These sources, while not large-scale RCTs or formal guideline statements, provide some empirical support that a definable clinical entity associated with chronic inflammatory responses to biotoxins can be identified and treated within specialized practice models. ^[28]

Contradicts

Mainstream guidelines and major evidence-based bodies do not currently recognize CIRS as an established diagnosis. ^[29][27] A clinical policy review states explicitly that chronic inflammatory response syndrome is considered an investigational or not clinically proven diagnosis and therefore not medically necessary, noting that it is not recognized as a pathologic entity in major biomedical databases, lacks an ICD coding designation, and has no unifying clinical studies that establish a clear disease entity linking proposed laboratory and environmental findings. ^[32] This review emphasizes inconsistent definitions, limited large-scale studies, and reliance on single-author narrative reviews that may not have undergone robust peer review. Broader guideline documents on hypertension, parenteral nutrition, and clinical nutrition in inflammatory bowel disease focus extensively on chronic inflammation as a mechanism but do not mention CIRS or endorse it as a distinct syndrome. ^[28][30][33] Overall, the available high-quality guideline-level evidence either ignores CIRS altogether or explicitly classifies it as unproven, indicating that current evidence is considered too weak, too narrow in scope, or too methodologically limited to support widespread clinical adoption.

Mainstream view

The mainstream medical position is that chronic inflammation is a key driver of many diseases, but Chronic Inflammatory Response Syndrome, as defined in Shoemaker-style protocols, is not an established, widely accepted diagnostic entity. ^[32][33] Major specialty guidelines for cardiovascular disease, parenteral nutrition, and inflammatory bowel disease address chronic inflammatory mechanisms and management without recognizing CIRS as a formal syndrome. ^[27][28][30] Health-plan and policy reviews explicitly classify CIRS as investigational and not clinically proven, citing the absence of consensus diagnostic criteria across mainstream organizations, lack of ICD coding, and insufficient large, independent, peer‑reviewed trials linking proposed biomarkers and environmental exposures into a validated disease construct. ^[34] Within functional and integrative medicine circles, CIRS is more often regarded as a real but emerging condition with a growing research base, yet mainstream academic and regulatory bodies continue to treat it as experimental and controversial pending more rigorous, independent, and large-scale evidence. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).

In their own wordsView sourceArchived copy

“#mold”

Rule: K.S.A. 65-2912(a)(6)-(7)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure Blood sugar dysfunction.

Blood sugar dysfunction

Supports

The broad concept that blood sugar dysfunction (e. g. , impaired fasting glucose, insulin resistance, type 2 diabetes) is a real and clinically important condition is strongly supported by extensive epidemiologic and interventional research as well as major diabetes guidelines, which recognize abnormal glucose homeostasis as a key risk factor for microvascular and macrovascular disease. High‑quality evidence shows that certain dietary fibers and foods can modestly improve markers of blood sugar dysfunction (fasting glucose, HbA1c, HOMA‑IR) in adults with prediabetes or type 2 diabetes, supporting the idea that the condition is modifiable rather than fixed. ^[38] A GRADE‑assessed systematic review and meta‑analysis of 19 randomized controlled trials found that psyllium supplementation significantly reduced fasting blood sugar, HbA1c, and HOMA‑IR compared with placebo, indicating that dietary soluble fiber can improve glycemic control and insulin resistance in adults with elevated blood sugar. ^[39] Earlier meta‑analytic work on psyllium also showed that multi‑week dosing before meals improves fasting blood glucose and HbA1c in patients with type 2 diabetes, with greater effects in those with worse baseline control, reinforcing that blood sugar dysfunction responds to targeted interventions. Systematic reviews and meta‑analyses of flaxseed supplementation report statistically significant reductions in fasting blood sugar, insulin, HbA1c, and HOMA‑IR in populations with prediabetes and type 2 diabetes, further supporting the concept that abnormal glucose and insulin resistance are clinically tractable. ^[40][41] The existence of multiple recent grade‑assessed systematic reviews and meta‑analyses on foods, fibers, probiotics, and botanicals targeting fasting glucose, HbA1c, insulin, and HOMA‑IR underscores that blood sugar dysfunction is a well‑recognized clinical entity and an accepted therapeutic target in mainstream research and guidelines.

Contradicts

The influencer’s claim is extremely vague (“Blood sugar dysfunction”) and does not specify a mechanism, prevalence, or a particular nonstandard diagnostic category; mainstream evidence supports clinically defined dysglycemia but does not endorse broad, undefined notions of “blood sugar dysfunction” as a catch‑all explanation for diverse symptoms without appropriate testing. Although the psyllium meta‑analysis reports statistically significant improvements in fasting blood sugar, HbA1c, and HOMA‑IR, the average effect sizes are modest, and subgroup analyses show that lower doses and shorter durations may have non‑significant effects, indicating that changes in blood sugar dysfunction are not large or universal and depend on dose, duration, and baseline status. ^[38][39][40] Meta‑analyses of flaxseed show benefit on some glycemic markers but not consistently on HbA1c, and individual randomized trials in prediabetes have found no significant effects of flaxseed on fasting glucose, insulin, or HOMA‑IR, highlighting that specific dietary components are not reliable stand‑alone fixes for blood sugar dysfunction across all populations. ^[41] Because the claim as stated does not specify diagnostic criteria, magnitude of risk, or evidence‑based interventions, it conflicts with the more precise, guideline‑based approach that defines impaired fasting glucose, impaired glucose tolerance, and diabetes using standardized thresholds and treats them with individualized lifestyle and pharmacologic strategies.

Mainstream view

Mainstream medicine recognizes blood sugar dysfunction under specific diagnostic categories such as impaired fasting glucose, impaired glucose tolerance, prediabetes, and type 2 diabetes, defined by standardized thresholds for fasting plasma glucose, 2‑hour oral glucose tolerance test, and HbA1c set by organizations like the American Diabetes Association and WHO. ^[38][39] The prevailing view is that chronic dysglycemia and insulin resistance are common, multifactorial conditions driven by genetics, excess adiposity, physical inactivity, diet quality, and other factors, and they are major risk factors for cardiovascular disease, kidney disease, neuropathy, and retinopathy. Mainstream guidelines recommend structured lifestyle interventions (weight reduction, increased physical activity, dietary patterns high in whole grains and fiber and low in refined carbohydrates and added sugars) plus evidence‑based pharmacologic therapies (e. g. , metformin, GLP‑1 receptor agonists, SGLT2 inhibitors, insulin when needed) to prevent progression of blood sugar dysfunction and reduce complications. Foods and supplements like psyllium, flaxseed, and other high‑fiber or plant‑based interventions are viewed as potentially helpful adjuncts that can modestly improve fasting glucose, HbA1c, and insulin resistance in some patients Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim). ^[40][41]

In their own wordsView sourceArchived copy

“Blood sugar dysfunction”

Rule: K.S.A. 65-2912(a)(6)-(7)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure Chronic inflammatory conditions.

Chronic inflammatory conditions

No specific health claims of theirs were cross-checked against the literature.

In their own wordsView sourceArchived copy

“Chronic inflammatory conditions”

Rule: K.S.A. 65-2912(a)(

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to advertise I had the brain of a 70-year-old as within their scope of practice.

I had the brain of a 70-year-old

No specific health claims of theirs were cross-checked against the literature.

In their own wordsView sourceArchived copy

“the brain of a 70-year-old”

Rule: K.S.A. §65-2871 (Kansas Healing Arts Act)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to advertise even severe brain degeneration can be reversed as within their scope of practice.

even severe brain degeneration can be reversed

No specific health claims of theirs were cross-checked against the literature.

In their own wordsView sourceArchived copy

“even severe brain degeneration can be reversed”

Rule: K.S.A. §65-2871 (Kansas Healing Arts Act)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure functional medicine.

functional medicine

Supports

There is limited peer‑reviewed evidence evaluating functional medicine as a distinct, validated medical model. ^[43] Some academic reviews describe functional medicine as a systems‑biology, patient‑centered framework that uses evidence‑based modalities such as nutrition, exercise, stress reduction, and certain medications or supplements, all of which individually have supportive evidence in conventional medicine for chronic disease prevention and management. ^[42] Observational outcome data (e. g. , quality‑of‑life or practice‑based cohorts) have reported patient‑reported improvements after care delivered in a functional‑medicine style clinic, but these are not randomized trials and mainly show associations rather than causation. ^[44] Lifestyle and nutrition interventions that functional medicine often employs—such as improving diet quality, physical activity, sleep, and stress management—are strongly supported by mainstream RCTs, guidelines, and systematic reviews, but these trials typically evaluate the interventions themselves, not “functional medicine” branding or its broader diagnostic/testing paradigm.

Contradicts

Major mainstream bodies have explicitly judged the overall evidence base for functional medicine to be insufficient. ^[43] A formal review by the American Academy of Family Physicians concluded there was not enough high‑quality evidence to support teaching functional medicine practice techniques in accredited continuing education, and noted that some claims and treatments promoted under the functional‑medicine banner may be potentially dangerous because they rely on unvalidated tests and supplement regimens rather than guideline‑based care. ^[42] Independent academic and science‑communication critiques describe functional medicine as a rebranding of complementary and alternative medicine, highlight its frequent use of unproven diagnoses (such as adrenal fatigue) and extensive biochemical testing of unproven clinical value, and emphasize that there are no robust randomized controlled trials or large, high‑quality comparative effectiveness studies demonstrating that the functional‑medicine model, as a package, improves hard outcomes (mortality, major morbidity, health‑care utilization) beyond standard, evidence‑based care. ^[44] Publications promoting functional medicine approaches to specific conditions (for example, long COVID) acknowledge that underlying pathophysiology and treatments remain poorly defined and that suggested protocols rely on extrapolation, low‑level evidence, and expert opinion rather than rigorous trials, underscoring that the model is largely hypothesis‑driven and not yet validated. Overall, high‑quality systematic reviews, meta‑analyses, and major guidelines do not endorse functional medicine itself as an evidence‑based, superior medical paradigm; instead, they support selected lifestyle or nutrition components that functional‑medicine practitioners also use but which are already part of conventional preventive and chronic‑disease care.

Mainstream view

Mainstream medicine views functional medicine as a loosely defined, alternative or integrative framework that borrows many legitimate, evidence‑based tools (nutrition counseling, exercise prescriptions, risk‑factor modification) but wraps them in a broader practice model that lacks rigorous validation and often incorporates unproven testing, diagnoses, and supplement protocols. ^[42][43] Leading professional societies do not recognize functional medicine as a formal medical specialty, and large clinical guidelines do not recommend seeking “functional medicine” per se; instead, they emphasize evidence‑based lifestyle and pharmacologic interventions delivered within conventional care. The prevailing position is that while some individual interventions used by functional‑medicine practitioners are strongly evidence‑based, the branded functional‑medicine model—especially its extensive, non‑standard laboratory panels, root‑cause narratives, and supplement‑heavy regimens—does not have sufficient high‑quality RCTs, comparative trials, or guideline support to be considered a validated, superior approach to diagnosis or treatment, and should be approached with caution, using standard evidence‑based medicine as the primary framework. ^[44] Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).

In their own wordsView sourceArchived copy

“#functionalmedicine”

Rule: K.S.A. §65-2871 (Kansas Healing Arts Act)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure Claims to manage blood sugar dysfunction, an endocrine/metabolic problem.

Claims to manage blood sugar dysfunction, an endocrine/metabolic problem

Supports

The broad concept that blood sugar dysfunction (e. g. , impaired fasting glucose, insulin resistance, type 2 diabetes) is a real and clinically important condition is strongly supported by extensive epidemiologic and interventional research as well as major diabetes guidelines, which recognize abnormal glucose homeostasis as a key risk factor for microvascular and macrovascular disease. High‑quality evidence shows that certain dietary fibers and foods can modestly improve markers of blood sugar dysfunction (fasting glucose, HbA1c, HOMA‑IR) in adults with prediabetes or type 2 diabetes, supporting the idea that the condition is modifiable rather than fixed. ^[38] A GRADE‑assessed systematic review and meta‑analysis of 19 randomized controlled trials found that psyllium supplementation significantly reduced fasting blood sugar, HbA1c, and HOMA‑IR compared with placebo, indicating that dietary soluble fiber can improve glycemic control and insulin resistance in adults with elevated blood sugar. ^[39] Earlier meta‑analytic work on psyllium also showed that multi‑week dosing before meals improves fasting blood glucose and HbA1c in patients with type 2 diabetes, with greater effects in those with worse baseline control, reinforcing that blood sugar dysfunction responds to targeted interventions. Systematic reviews and meta‑analyses of flaxseed supplementation report statistically significant reductions in fasting blood sugar, insulin, HbA1c, and HOMA‑IR in populations with prediabetes and type 2 diabetes, further supporting the concept that abnormal glucose and insulin resistance are clinically tractable. ^[40][41] The existence of multiple recent grade‑assessed systematic reviews and meta‑analyses on foods, fibers, probiotics, and botanicals targeting fasting glucose, HbA1c, insulin, and HOMA‑IR underscores that blood sugar dysfunction is a well‑recognized clinical entity and an accepted therapeutic target in mainstream research and guidelines.

Contradicts

The influencer’s claim is extremely vague (“Blood sugar dysfunction”) and does not specify a mechanism, prevalence, or a particular nonstandard diagnostic category; mainstream evidence supports clinically defined dysglycemia but does not endorse broad, undefined notions of “blood sugar dysfunction” as a catch‑all explanation for diverse symptoms without appropriate testing. Although the psyllium meta‑analysis reports statistically significant improvements in fasting blood sugar, HbA1c, and HOMA‑IR, the average effect sizes are modest, and subgroup analyses show that lower doses and shorter durations may have non‑significant effects, indicating that changes in blood sugar dysfunction are not large or universal and depend on dose, duration, and baseline status. ^[38][39][40] Meta‑analyses of flaxseed show benefit on some glycemic markers but not consistently on HbA1c, and individual randomized trials in prediabetes have found no significant effects of flaxseed on fasting glucose, insulin, or HOMA‑IR, highlighting that specific dietary components are not reliable stand‑alone fixes for blood sugar dysfunction across all populations. ^[41] Because the claim as stated does not specify diagnostic criteria, magnitude of risk, or evidence‑based interventions, it conflicts with the more precise, guideline‑based approach that defines impaired fasting glucose, impaired glucose tolerance, and diabetes using standardized thresholds and treats them with individualized lifestyle and pharmacologic strategies.

Mainstream view

Mainstream medicine recognizes blood sugar dysfunction under specific diagnostic categories such as impaired fasting glucose, impaired glucose tolerance, prediabetes, and type 2 diabetes, defined by standardized thresholds for fasting plasma glucose, 2‑hour oral glucose tolerance test, and HbA1c set by organizations like the American Diabetes Association and WHO. ^[38][39] The prevailing view is that chronic dysglycemia and insulin resistance are common, multifactorial conditions driven by genetics, excess adiposity, physical inactivity, diet quality, and other factors, and they are major risk factors for cardiovascular disease, kidney disease, neuropathy, and retinopathy. Mainstream guidelines recommend structured lifestyle interventions (weight reduction, increased physical activity, dietary patterns high in whole grains and fiber and low in refined carbohydrates and added sugars) plus evidence‑based pharmacologic therapies (e. g. , metformin, GLP‑1 receptor agonists, SGLT2 inhibitors, insulin when needed) to prevent progression of blood sugar dysfunction and reduce complications. Foods and supplements like psyllium, flaxseed, and other high‑fiber or plant‑based interventions are viewed as potentially helpful adjuncts that can modestly improve fasting glucose, HbA1c, and insulin resistance in some patients Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim). ^[40][41]

In their own wordsView sourceArchived copy

“Blood sugar dysfunction”

Rule: K.S.A. §65-2871 (Kansas Healing Arts Act)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure Claims functional medicine diagnosis of root causes for chronic disease.

Claims functional medicine diagnosis of root causes for chronic disease

Supports

There is limited peer‑reviewed evidence evaluating functional medicine as a distinct, validated medical model. ^[43] Some academic reviews describe functional medicine as a systems‑biology, patient‑centered framework that uses evidence‑based modalities such as nutrition, exercise, stress reduction, and certain medications or supplements, all of which individually have supportive evidence in conventional medicine for chronic disease prevention and management. ^[42] Observational outcome data (e. g. , quality‑of‑life or practice‑based cohorts) have reported patient‑reported improvements after care delivered in a functional‑medicine style clinic, but these are not randomized trials and mainly show associations rather than causation. ^[44] Lifestyle and nutrition interventions that functional medicine often employs—such as improving diet quality, physical activity, sleep, and stress management—are strongly supported by mainstream RCTs, guidelines, and systematic reviews, but these trials typically evaluate the interventions themselves, not “functional medicine” branding or its broader diagnostic/testing paradigm.

Contradicts

Major mainstream bodies have explicitly judged the overall evidence base for functional medicine to be insufficient. ^[43] A formal review by the American Academy of Family Physicians concluded there was not enough high‑quality evidence to support teaching functional medicine practice techniques in accredited continuing education, and noted that some claims and treatments promoted under the functional‑medicine banner may be potentially dangerous because they rely on unvalidated tests and supplement regimens rather than guideline‑based care. ^[42] Independent academic and science‑communication critiques describe functional medicine as a rebranding of complementary and alternative medicine, highlight its frequent use of unproven diagnoses (such as adrenal fatigue) and extensive biochemical testing of unproven clinical value, and emphasize that there are no robust randomized controlled trials or large, high‑quality comparative effectiveness studies demonstrating that the functional‑medicine model, as a package, improves hard outcomes (mortality, major morbidity, health‑care utilization) beyond standard, evidence‑based care. ^[44] Publications promoting functional medicine approaches to specific conditions (for example, long COVID) acknowledge that underlying pathophysiology and treatments remain poorly defined and that suggested protocols rely on extrapolation, low‑level evidence, and expert opinion rather than rigorous trials, underscoring that the model is largely hypothesis‑driven and not yet validated. Overall, high‑quality systematic reviews, meta‑analyses, and major guidelines do not endorse functional medicine itself as an evidence‑based, superior medical paradigm; instead, they support selected lifestyle or nutrition components that functional‑medicine practitioners also use but which are already part of conventional preventive and chronic‑disease care.

Mainstream view

Mainstream medicine views functional medicine as a loosely defined, alternative or integrative framework that borrows many legitimate, evidence‑based tools (nutrition counseling, exercise prescriptions, risk‑factor modification) but wraps them in a broader practice model that lacks rigorous validation and often incorporates unproven testing, diagnoses, and supplement protocols. ^[42][43] Leading professional societies do not recognize functional medicine as a formal medical specialty, and large clinical guidelines do not recommend seeking “functional medicine” per se; instead, they emphasize evidence‑based lifestyle and pharmacologic interventions delivered within conventional care. The prevailing position is that while some individual interventions used by functional‑medicine practitioners are strongly evidence‑based, the branded functional‑medicine model—especially its extensive, non‑standard laboratory panels, root‑cause narratives, and supplement‑heavy regimens—does not have sufficient high‑quality RCTs, comparative trials, or guideline support to be considered a validated, superior approach to diagnosis or treatment, and should be approached with caution, using standard evidence‑based medicine as the primary framework. ^[44] Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).

In their own wordsView sourceArchived copy

“#functionalmedicine”

Rule: K.S.A. §65-2871 (Kansas Healing Arts Act)

Jonah Dallas Yakel is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to advertise Functional medicine root-cause programs for chronic disease as within their scope of practice.

Functional medicine root-cause programs for chronic disease

Supports

There is limited peer‑reviewed evidence evaluating functional medicine as a distinct, validated medical model. ^[43] Some academic reviews describe functional medicine as a systems‑biology, patient‑centered framework that uses evidence‑based modalities such as nutrition, exercise, stress reduction, and certain medications or supplements, all of which individually have supportive evidence in conventional medicine for chronic disease prevention and management. ^[42] Observational outcome data (e. g. , quality‑of‑life or practice‑based cohorts) have reported patient‑reported improvements after care delivered in a functional‑medicine style clinic, but these are not randomized trials and mainly show associations rather than causation. ^[44] Lifestyle and nutrition interventions that functional medicine often employs—such as improving diet quality, physical activity, sleep, and stress management—are strongly supported by mainstream RCTs, guidelines, and systematic reviews, but these trials typically evaluate the interventions themselves, not “functional medicine” branding or its broader diagnostic/testing paradigm.

Contradicts

Major mainstream bodies have explicitly judged the overall evidence base for functional medicine to be insufficient. ^[43] A formal review by the American Academy of Family Physicians concluded there was not enough high‑quality evidence to support teaching functional medicine practice techniques in accredited continuing education, and noted that some claims and treatments promoted under the functional‑medicine banner may be potentially dangerous because they rely on unvalidated tests and supplement regimens rather than guideline‑based care. ^[42] Independent academic and science‑communication critiques describe functional medicine as a rebranding of complementary and alternative medicine, highlight its frequent use of unproven diagnoses (such as adrenal fatigue) and extensive biochemical testing of unproven clinical value, and emphasize that there are no robust randomized controlled trials or large, high‑quality comparative effectiveness studies demonstrating that the functional‑medicine model, as a package, improves hard outcomes (mortality, major morbidity, health‑care utilization) beyond standard, evidence‑based care. ^[44] Publications promoting functional medicine approaches to specific conditions (for example, long COVID) acknowledge that underlying pathophysiology and treatments remain poorly defined and that suggested protocols rely on extrapolation, low‑level evidence, and expert opinion rather than rigorous trials, underscoring that the model is largely hypothesis‑driven and not yet validated. Overall, high‑quality systematic reviews, meta‑analyses, and major guidelines do not endorse functional medicine itself as an evidence‑based, superior medical paradigm; instead, they support selected lifestyle or nutrition components that functional‑medicine practitioners also use but which are already part of conventional preventive and chronic‑disease care.

Mainstream view

Mainstream medicine views functional medicine as a loosely defined, alternative or integrative framework that borrows many legitimate, evidence‑based tools (nutrition counseling, exercise prescriptions, risk‑factor modification) but wraps them in a broader practice model that lacks rigorous validation and often incorporates unproven testing, diagnoses, and supplement protocols. ^[42][43] Leading professional societies do not recognize functional medicine as a formal medical specialty, and large clinical guidelines do not recommend seeking “functional medicine” per se; instead, they emphasize evidence‑based lifestyle and pharmacologic interventions delivered within conventional care. The prevailing position is that while some individual interventions used by functional‑medicine practitioners are strongly evidence‑based, the branded functional‑medicine model—especially its extensive, non‑standard laboratory panels, root‑cause narratives, and supplement‑heavy regimens—does not have sufficient high‑quality RCTs, comparative trials, or guideline support to be considered a validated, superior approach to diagnosis or treatment, and should be approached with caution, using standard evidence‑based medicine as the primary framework. ^[44] Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).

In their own wordsView sourceArchived copy

“#functionalmedicine”

Rule: K.S.A. §65-2871 (Kansas Healing Arts Act)

Jonah Dallas Yakel is not approved to offer Detoxification protocols within a Chiropractor scope of practice under Kansas State Board of Healing Arts (Chiropractic).

Detoxification protocols

No specific health claims of theirs were cross-checked against the literature.

In their own wordsView sourceArchived copy

“environmental remediation to detoxification protocols, brain repair, and lifestyle modifications”

Rule: K.S.A. §65-2871 (Kansas Healing Arts Act)